Skip to main content

Table 1 Estimated target population

From: Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

   % Reference N
1 Patients with lung cancer in 2020 (18) 28,475
2 Patients with NSCLC 85.0% (3) 24,204
3 Stage VI in samples of NSCLC patients 54.5% (19) 13,191
4 Patients with stage IV NSCLC non-squamous subtype 66.9% (20) 8825
5 Patients with stage IV NSCLC squamous subtype 33.1% (20) 4366
6 Patients with stage IV NSCLC squamous subtype, never smokers 16.0% (21) 699
7 Candidate for ALK rearrangement diagnosis (steps 4 + 6) 9523
8 Patients finally tested for ALK (testing rate) 80.1% (22) 7628
  1. NSCLC Non-small cell lung cancer, ALK anaplastic lymphoma kinase